Tags

Type your tag names separated by a space and hit enter

Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.
Br J Haematol. 2020 Jun 25 [Online ahead of print]BJ

Abstract

Coronavirus disease 2019 (COVID-19), caused by novel SARS-CoV-2, leads to significant mortality and morbidity with increasing evidence for inflammatory pathways being implicated in the lung damage it causes. (1,2) Severe COVID-19 patients present with increased inflammatory markers, akin to secondary haemophagocytic lymphohistiocytosis (sHLH), that have been shown to predict mortality. (3,4) There is emerging evidence for the use of an interleukin 6 (IL-6) inhibitor, tocilizumab (TCZ), for suppression of the inflammatory cytokine storm in this context. (5-7) Ruxolitinib (RXB), a JAK-STAT inhibitor, has also been shown to have proven efficacy in the treatment of sHLH. (8) Both agents appear to be promising in the fight against SARS-CoV-2 infection, (9,10) leading to an increasing number of trials being registered with their use. (11,12) Until this point, no single agent has shown a survival benefit against SARS-CoV-2 and it is possible that monotherapy may not suppress inflammation enough to overcome the COVID-19 related cytokine storm and hyper-inflammation.

Authors+Show Affiliations

Royal Berkshire Hospital NHS Foundation Trust, Reading, United Kingdom.Royal Berkshire Hospital NHS Foundation Trust, Reading, United Kingdom.Royal Berkshire Hospital NHS Foundation Trust, Reading, United Kingdom.Royal Berkshire Hospital NHS Foundation Trust, Reading, United Kingdom.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32584421

Citation

Portsmore, Sophie, et al. "Combined IL-6 and JAK-STAT Inhibition Therapy in COVID-19 Related sHLH, Potential Game Changer." British Journal of Haematology, 2020.
Portsmore S, Tran Nguyen TN, Beacham E, et al. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer. Br J Haematol. 2020.
Portsmore, S., Tran Nguyen, T. N., Beacham, E., & Neelakantan, P. (2020). Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer. British Journal of Haematology. https://doi.org/10.1111/bjh.16966
Portsmore S, et al. Combined IL-6 and JAK-STAT Inhibition Therapy in COVID-19 Related sHLH, Potential Game Changer. Br J Haematol. 2020 Jun 25; PubMed PMID: 32584421.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer. AU - Portsmore,Sophie, AU - Tran Nguyen,Thien Ngoc, AU - Beacham,Emma, AU - Neelakantan,Pratap, Y1 - 2020/06/25/ PY - 2020/6/26/entrez PY - 2020/6/26/pubmed PY - 2020/6/26/medline KW - Ruxolitinib KW - Tocilizumab KW - cytokine storm KW - sHLH KW - severe COVID JF - British journal of haematology JO - Br. J. Haematol. N2 - Coronavirus disease 2019 (COVID-19), caused by novel SARS-CoV-2, leads to significant mortality and morbidity with increasing evidence for inflammatory pathways being implicated in the lung damage it causes. (1,2) Severe COVID-19 patients present with increased inflammatory markers, akin to secondary haemophagocytic lymphohistiocytosis (sHLH), that have been shown to predict mortality. (3,4) There is emerging evidence for the use of an interleukin 6 (IL-6) inhibitor, tocilizumab (TCZ), for suppression of the inflammatory cytokine storm in this context. (5-7) Ruxolitinib (RXB), a JAK-STAT inhibitor, has also been shown to have proven efficacy in the treatment of sHLH. (8) Both agents appear to be promising in the fight against SARS-CoV-2 infection, (9,10) leading to an increasing number of trials being registered with their use. (11,12) Until this point, no single agent has shown a survival benefit against SARS-CoV-2 and it is possible that monotherapy may not suppress inflammation enough to overcome the COVID-19 related cytokine storm and hyper-inflammation. SN - 1365-2141 UR - https://www.unboundmedicine.com/medline/citation/32584421/Combined_IL_6_and_JAK_STAT_inhibition_therapy_in_COVID_19_related_sHLH_potential_game_changer_ L2 - https://doi.org/10.1111/bjh.16966 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.